Efficacy and safety of semaglutide in patients with heart failure: A meta-analysis

Abstract

Background: The pleiotropic effects of semaglutide make it a breakthrough therapy for managing diabetes and obesity, particularly in patients with comorbid cardiovascular diseases. However, its clinical application in heart failure (HF) remains under investigation.

Objective: To systematically evaluate the efficacy and safety of subcutaneous semaglutide in the treatment of HF, irrespective of obesity status or the presence of type 2 diabetes mellitus (T2DM).

Methods: A comprehensive search of the Cochrane Library, PubMed, Embase, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases was conducted to identify randomized controlled trials (RCTs) of subcutaneous semaglutide in HF patients, from inception to November 2, 2024. RevMan 5.3 software was used for statistical analysis.

Results: A total of 4 RCTs involving 6109 patients were included. Four RCTs involving 6109 patients were included. Meta-analysis showed that, compared with placebo, subcutaneous semaglutide reduced the risks of cardiovascular death (RR = 0.75, 95 % CI: 0.61-0.92, P = 0.005), all-cause mortality (RR = 0.81, 95 % CI: 0.67-0.98, P = 0.03), and serious adverse events (RR = 0.53, 95 % CI: 0.41-0.68, P < 0.00001). Subgroup analysis revealed that semaglutide improved Kansas City Cardiomyopathy Questionnaire clinical summary scores (KCCQ-CSS) (MD = 7.58, 95 % CI: 4.40-10.77, P < 0.00001) and 6-minute walk test (6-MWT) distances (MD = 16.91, 95 % CI: 8.98-24.83, P < 0.0001), and reduced the risk of HF rehospitalization (RR = 0.41, 95 % CI: 0.26-0.65, P = 0.0001) in obese patients with HFpEF. Among patients without T2DM, semaglutide was superior to placebo in reducing HF rehospitalization (RR = 0.16, 95 % CI: 0.04-0.68, P = 0.01) and cardiovascular mortality (RR = 0.76, 95 % CI: 0.60-0.97, P = 0.03). Furthermore, at a dose of 2.4 mg weekly, semaglutide reduced HF rehospitalization (RR = 0.29, 95 % CI: 0.14-0.58, P = 0.0005) and cardiovascular mortality (RR = 0.75, 95 % CI: 0.59-0.95, P = 0.02) compared with placebo, whereas no significant benefit was observed at a dose of 1.0 mg weekly.

Conclusion: Current evidence suggests that subcutaneous semaglutide safely and effectively reduces cardiovascular mortality, all-cause mortality, and serious adverse events in patients with HF, improves quality of life and exercise tolerance in obese HFpEF patients, and lowers the risk of HF rehospitalization. Nevertheless, given the limited number of included trials and patient populations, further high-quality studies are warranted to confirm these findings.

Keywords

Semaglutide / Heart failure / Efficacy / Safety / Meta-analysis

Declarations

Not applicable.

Authors’ contributions

Xueni Li: Conceptualization, Methodology, Investigation, Data Curation, Formal Analysis, Writing-Original Draft. Gejing Liu: Methodology, Investigation, Data Curation, Formal Analysis. Yongming Liu: Supervision, Project Administration, Validation, Writing-Review & Editing. All authors contributed to the article and approved the submitted version.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This study was supported by the Gansu Provincial Science and Technology Plan Project (No. 20YF8FA079) and the 2023 Lanzhou Municipal Science and Technology Development Guidance Plan Project (No. 2023-ZD-96).

Declarations of Competing Interests

The authors declare no competing interests.

Acknowledgements

Not applicable.

Authors' other information

Not applicable.

References

[1] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032. https://doi.org/10.1161/CIR.0000000000001063

[2] Chinese Society of Cardiology CMA, Physician CCo.C, Association CHFAo.CMD, et al. Chinese guidelines for the diagnosis and treatment of heart failure 2024. Zhonghua xin xue guan Bing za zhi. 2024; 52(3):235-275. https://doi.org/10.3760/cma.j.cn112148-20231101-00405

[3] Pandey A, Khan MS, Patel KV, et al. Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes Endocrinol. 2023; 11(8):607-624. https://doi.org/10.1016/S2213-8587(23)00128-6

[4] Butt JH, Petrie MC, Jhund PS, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023; 44(13):1136-1153. https://doi.org/10.1093/eurheartj/ehad083

[5] Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol (Lausanne). 2021; 12:721135. https://doi.org/10.3389/fendo.2021.721135

[6] Yang XD, Yang YY. Clinical pharmacokinetics of semaglutide: a systematic review. Drug Des Dev Ther. 2024; 18:2555-2570. https://doi.org/10.2147/DDDT.S470826

[7] Moiz A, Filion KB, Tsoukas MA, et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025; 138(6):934-940. https://doi.org/10.1016/j.amjmed.2025.01.021

[8] Romera I, Cebrián-Cuenca A, Álvarez-Guisasola F, et al. A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes. Diabetes Ther. 2019; 10(1):5-19. https://doi.org/10.1007/s13300-018-0535-9

[9] Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Invest Med. 2022; 70(1):5-13. https://doi.org/10.1136/jim-2021-001952

[10] Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141

[11] Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024; 404(10456):949-961. https://doi.org/10.1016/S0140-6736(24)01643-X

[12] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. https://doi.org/10.1136/bmj.n71

[13] Pratley RE, Tuttle KR, Rossing P, et al. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol. 2024; 84(17):1615-1628. https://doi.org/10.1016/j.jacc.2024.08.004

[14] Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024; 390(15):1394-1407. https://doi.org/10.1056/NEJMoa2313917

[15] Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023; 389(12):1069-1084. https://doi.org/10.1056/NEJMoa2306963

[16] Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024; 404(10454):773-786. https://doi.org/10.1016/S0140-6736(24)01498-3

[17] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023; 389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563

[18] Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024; 391(2):109-121. https://doi.org/10.1056/NEJMoa2403347

[19] Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017; 19(1):69-77. https://doi.org/10.1002/ejhf.657

[20] Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016; 316(5):500-508. https://doi.org/10.1001/jama.2016.10260

[21] Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024; 15:1431292. https://doi.org/10.3389/fendo.2024.1431292

[22] Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020; 22(3):442-451. https://doi.org/10.1111/dom.13955

[23] Caruso I, Cignarelli A, Giorgino F. Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials. Trends Endocrinol Metab. 2019; 30(9):578-589. https://doi.org/10.1016/j.tem.2019.07.004

[24] Yue L, Chen S, Ren Q, et al. Effects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice. Front Endocrinol (Lausanne). 2022; 13:995007. https://doi.org/10.3389/fendo.2022.995007

[25] He W, Wei J, Liu X, et al. Semaglutide ameliorates pressure overload-induced cardiac hypertrophy by improving cardiac mitophagy to suppress the activation of NLRP 3 inflammasome. Sci Rep. 2024; 14(1):11824. https://doi.org/10.1038/s41598-024-62465-6

[26] García-Vega D, Sánchez-López D, Rodríguez-Carnero G, et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovasc Diabetol. 2024; 23(1):1. https://doi.org/10.1186/s12933-023-02096-9

[27] Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024; 403(10437):1635-1648. https://doi.org/10.1016/S0140-6736(24)00469-0

[28] Rodríguez Jiménez B, Rodríguez de Vera Gómez P, Belmonte Lomas S, et al. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2024; 15:1386542. https://doi.org/10.3389/fendo.2024.1386542

[29] Solomon SD, Ostrominski JW, Wang X, et al. Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure. J Am Coll Cardiol. 2024; 84(17):1587-1602. https://doi.org/10.1016/j.jacc.2024.08.021

[30] Nielsen J, Narayan KV, Cunningham SA. Incidence of obesity across adulthood in the United States, 2001-2017-a national prospective analysis. Am J Clin Nutr. 2023; 117(1):141-148. https://doi.org/10.1016/j.ajcnut.2022.10.012

[31] Nanda M, Sharma R, Mubarik S, et al. Type-2 diabetes mellitus (T2DM): spatial-temporal patterns of incidence, mortality and attributable risk factors from 1990 to 2019 among 21 world regions. Endocrine. 2022; 77(3):444-454. https://doi.org/10.1007/s12020-022-03125-5

[32] Dong B, Zhao Y, Wang J, et al. Epidemiological analysis of chronic kidney disease from 1990 to 2019 and predictions to 2030 by Bayesian age-period-cohort analysis. Ren Fail. 2024; 46(2):2403645. https://doi.org/10.1080/0886022X.2024.2403645

[33] DeJesus RS, Croghan IT, Jacobson DJ, et al. Incidence of obesity at 1 and 3 years among community dwelling adults: a population-based study. J Prim Care Community Health. 2022; 13:21501319211068632. https://doi.org/10.1177/21501319211068632

[34] Gerhardt T, Gerhardt L, Ouwerkerk W, et al. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study. Lancet Glob Health. 2023; 11(12):e1874-e1884. https://doi.org/10.1016/S2214-109X(23)00408-4

[35] Elgendy IY, Pepine CJ. Heart failure with preserved ejection fraction: is ischemia due to coronary microvascular dysfunction a mechanistic factor. Am J Med. 2019; 132(6):692-697. https://doi.org/10.1016/j.amjmed.2018.12.038

[36] Savji N, Meijers WC, Bartz TM, et al. The association of obesity and cardiometabolic traits with incident HFpEF and HFrEF. JACC Heart Fail. 2018; 6(8):701-709. https://doi.org/10.1016/j.jchf.2018.05.018

[37] Kapitza C, Dahl K, Jacobsen JB, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017; 60(8):1390-1399. https://doi.org/10.1007/s00125-017-4289-0

[38] Liu Y, Ruan B, Jiang H, et al. The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr. 2023; 118(3):614-626. https://doi.org/10.1016/j.ajcnut.2023.04.017

[39] Chinese Diabetes Society. Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China (2024 Edition). Chinese Journal of Diabetes Mellitus, 2025; 17(1): 16-139. doi: 10.3760/cma.j.cn115791-20241203-00705.

[40] Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019; 7(10):776-785. https://doi.org/10.1016/S2213-8587(19)30249-9

[41] Su X, Wu MX. Disease management and optimization of pharmacological therapy for heart failure with reduced ejection fraction. Chin J Cardiovasc Med. 2023; 28(3):277-281. https://doi.org/10.3969/j.issn.1007-5410.2023.03.017

[42] Cardiovascular Physicians Branch of Chinese Medical Doctor Association, China Heart Failure Center Alliance, Working Group on Expert Consensus on Clinical Decision-Making Pathway for "New Quadruple" Drug Therapy of Chronic Heart Failure. Expert consensus on clinical decision-making pathway for "new quadruple" drug therapy of chronic heart failure. Chinese Circulation Journal, 2022; 37(8): 769-781. doi: 10.3969/j.issn.1000-3614.2022.08.003.

[43] Toth PP, Gauthier D. Heart failure with preserved ejection fraction: strategies for disease management and emerging therapeutic approaches. Post Med. 2021; 133(2):125-139. https://doi.org/10.1080/00325481.2020.1842620

[44] Borlaug BA, Sharma K, Shah SJ, et al. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023; 81(18):1810-1834. https://doi.org/10.1016/j.jacc.2023.01.049